°³ °üÀý¿° Ä¡·á ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2032³â±îÁö 4.7% ÀÌ»óÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Ö°ßÀÇ °í·ÉÈ¿Í ÇÔ²² ³ë·É°ßÀÇ ÈçÇÑ Áúº´ÀÎ °üÀý¿°ÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÅëÁõÀ» ¿ÏÈÇÏ°í ¾ÆÇ ¹Ý·Áµ¿¹°ÀÇ »îÀÇ ÁúÀ» °³¼±Çϱâ À§ÇÑ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °üÀý¿° Àç´Ü¿¡ µû¸£¸é °³ 5¸¶¸® Áß 1¸¶¸®°¡ °üÀý¿°À» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀº °üÀý¿°ÀÇ Áõ»ó°ú Á¶±â °³ÀÔÀÇ Á߿伺À» Á¡Á¡ ´õ ¸¹ÀÌ ÀνÄÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼öÀÇÇÐÀû °Ë»ç, Áø´Ü ¼ºñ½º ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ °·ÂÇÑ ¼ö¿ä·Î À̾îÁö°í ÀÖ½À´Ï´Ù.
¼öÀÇÇÐ ºÐ¾ßÀÇ ±â¼ú ¹ßÀü°ú Çõ½ÅÀÇ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs), Áúº´ º¯Çü °ñ°üÀý¿° Ä¡·áÁ¦(DMOADs), Áٱ⼼Æ÷ Ä¡·á¿Í °°Àº Àç»ý ¿ä¹ýÀ» Æ÷ÇÔÇÑ ½Å¾à °³¹ßÀº ¼öÀǻ翡°Ô °³ °üÀý¿°À» È¿°úÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ¼±ÅñÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¹°¸®Ä¡·á, ¼öÄ¡·á, °üÀý °Ç°º¸Á¶Á¦¿Í °°Àº ´ëü ¿ä¹ýÀÇ °¡¿ë¼º°ú Àαâ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í È®´ëÇÒ °ÍÀÔ´Ï´Ù.
°³ °üÀý¿° Ä¡·á »ê¾÷Àº Ä¡·á À¯Çü, °üÀý¿° À¯Çü ¹× Áö¿ªÀ¸·Î ºÐ·ùµË´Ï´Ù.
Ä¡·á À¯Çü¿¡ µû¶ó ¿Ü°úÀû Ä¡·á À¯ÇüÀÇ ½ÃÀå ±Ô¸ð´Â ¼öÀÇÇÐ ¼ö¼ú ±â¼úÀÇ ¹ßÀü°ú ¿Ü°úÀû °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ë Áõ°¡·Î ÀÎÇØ 2024³â¿¡¼ 2032³â »çÀÌ¿¡ Å« CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °üÀý°æ °Ë»ç, °üÀý ¼ö¼ú ¹× ±³Á¤ Àý°ñ¼ú°ú °°Àº ÀýÂ÷´Â °üÀý¿°ÀÌ ÁøÇàµÈ ¹Ý·Á°ßÀÇ À̵¿¼º°ú »îÀÇ ÁúÀ» Å©°Ô Çâ»ó½Ã۱⠶§¹®¿¡ Á¡Á¡ ´õ º¸Æíȵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¼úÀº ¼º°ø°ú °á°ú¸¦ °³¼±Çϱâ À§ÇØ ´õ ³ªÀº Áø´Ü µµ±¸¿Í ¼ö¼ú ÈÄ °ü¸®·Î µÞ¹ÞħµË´Ï´Ù.
°³ ·ù¸¶Æ¼½º °üÀý¿° Ä¡·á »ê¾÷Àº °³ÀÇ ÀÚ°¡¸é¿ª¼º °üÀý¿° Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í À̸¦ Ä¡·áÇÒ ¼ö Àִ ǥÀû Ä¡·á¹ýÀÌ °³¹ßµÇ¸é¼ 2032³â±îÁö ÀûÀýÇÑ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ·ù¸¶Æ¼½º °üÀý¿°Àº °³¿¡¼ °ñ°üÀý¿°º¸´Ù ´ú ÈçÇÑ ÁúȯÀÌÁö¸¸, ¹æÄ¡ÇÏ¸é ½ÉÇÑ ÅëÁõ°ú °üÀý ¼Õ»óÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼öÀÇÇÐÀÌ ¹ßÀüÇÔ¿¡ µû¶ó °³ ÀÚ°¡¸é¿ª¼º °üÀý¿°ÀÇ ±âº» ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ÀÌÇØ°¡ Çâ»óµÇ¾î Áúº´ º¯Çü ¾à¹° ¹× ¸é¿ª ¾ïÁ¦Á¦¿Í °°Àº »õ·Î¿î Ä¡·á¹ýÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù.
À¯·´ÀÇ °³ °üÀý¿° Ä¡·á »ê¾÷Àº 2024³âºÎÅÍ 2032³â±îÁö Áö¼ÓÀûÀÎ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â µ¿¹°¿ë ÀǾàǰÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁذú ÃÖ¼Òħ½À ¼ö¼úÀÇ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. Àß ±¸ÃàµÈ ¼öÀÇÇÐÀû ÀÎÇÁ¶ó¿Í ³ôÀº ¹Ý·Áµ¿¹° »çÀ°·ü·Î ÀÎÇØ Àü¹® °üÀý¿° Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¹æ Ä¡·áÀÇ Á߿伺°ú °üÀý¿° Ä¡·á Àü·«¿¡ ´ëÇÑ À¯·´ ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
Canine Arthritis Treatment Market size is expected to register over 4.7% CAGR between 2024 and 2032. With the rising number of aging dogs, the incidence of arthritis, which is a common disease in older dogs, is increasing. This is further driving the demand for effective treatments to relieve pain and improve the quality of life of the sick pets. As per Arthritis Foundation, canine arthritis affects one out of every five dogs. Pet owners have grown increasingly aware of the symptoms of arthritis and the importance of early intervention, leading to the strong demand for veterinary consultations, diagnostic services, and treatment solutions.
Growing technological advancements and innovations in veterinary medicine are also influencing the market growth. The development of new drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying osteoarthritis drugs (DMOADs), and regenerative therapies, such as stem cell therapy, is offering veterinarians a wider range of options for effective treatment of canine arthritis. The increasing availability and popularity of alternative therapies like physical therapy, hydrotherapy and joint health supplements will further expand the market growth.
The canine arthritis treatment industry is classified into treatment type, arthritis type and region.
Based on treatment type, the market size from the surgical procedure treatment type segment is slated to witness significant CAGR during 2024-2032, owing to advancements in veterinary surgical techniques and the increasing acceptance of surgical interventions. Procedures, such as arthroscopy, joint surgery and corrective osteotomies are becoming more common as they significantly improve mobility and quality of life in dogs with advanced arthritis. These operations are supported by better diagnostic tools and post-operative care for improving their success and results.
Canine arthritis treatment industry from the rheumatoid arthritis type segment is predicted to record decent growth rate through 2032, driven by the increasing recognition of autoimmune arthritis conditions in dogs and the development of targeted therapies to address them. Rheumatoid arthritis, although less common in dogs than osteoarthritis, can cause severe pain and joint damages if left untreated. With developments in veterinary medicine, understanding of the mechanisms underlying autoimmune arthritis in dogs is increasing, leading to the development of new treatment options, such as disease-modifying drugs and immunosuppressants.
Europe canine arthritis treatment industry is poised to depict sustained growth during 2024-2032, attributed to stringent regulatory standards for ensuring the safety and efficacy of veterinary pharmaceuticals along with the growing minimally invasive surgeries. The well-established veterinary infrastructure and high pet ownership rate are increasing the demand for specialized arthritis treatment. The strong emphasis on preventive treatment and the growing awareness of European pet owners about arthritis treatment strategies are also fueling the regional market growth.